<DOC>
	<DOCNO>NCT02890160</DOCNO>
	<brief_summary>The FUTURE-II study confirmative clinical trial Sirolimus Target Eluting Bioresorbable Vascular Scaffold ( Firesorb ) feasibility safety device preliminary confirm small-scale First-in-Man clinical trial .</brief_summary>
	<brief_title>A Trial Firesorb Patients With Coronary Artery Disease : FUTURE-II</brief_title>
	<detailed_description>This study prospective , multicenter , single-blind , randomize controlled trial patient coronary artery disease cause two de novo native coronary artery lesion separate epicardial vessel . The goal evaluate safety effectiveness Firesorb support approval Chinese Food Drug Administration ( CFDA ) product . The Abbott 's XIENCE Everolimus-eluting Coronary Stent System select control device . 610 subject recruit divide queue 1 ( n=430 ) queue 2 ( n=180 ) . All subject two queue 1:1 randomly assign experimental group control group . All subject undergo clinical follow-up 1-month , 6-month , 1-year , 2-year , 3-year , 4-year 5-year post-index procedure . Subjects queue 1 undergo angiographic follow-up 1-year post-index procedure ; 3-5 center specify subgroup complete OCT follow-up ( n=80 , 40 test control group ) . Subjects queue 2 undergo angiographic follow-up 2-year post-index procedure ; 40 subject complete OCT follow-up ( 20 test control group ) .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>General 1 . 1875 year age , male nonpregnant female ; 2 . With silent ischemia evidence , patient stable unstable angina , patient old myocardial infarction ; 3 . Patients indication coronary artery bypass graft surgery ; 4 . To understand purpose testing , voluntary inform consent , patient undergo invasive imaging followup . Angiographic 1 . One two de novo target lesion : 1 . If one target lesion , second nontarget lesion may treat nontarget lesion must present different epicardial vessel , must treat first successful , uncomplicated result prior randomization target lesion . 2 . If two target lesion present , must present different epicardial vessel must satisfy angiographic eligibility criterion . 3 . The definition epicardial vessel mean LAD , LCX RCA branch . Thus , patient must lesion require treatment e.g . LAD diagonal branch . 2 . Target lesion ( ) must locate native coronary artery visually estimate quantitatively assess % diameter stenosis ( DS ) ≥ 50 % &lt; 100 % thrombolysis myocardial infarction ( TIMI ) flow ≥1 one following : stenosis ≥ 70 % , abnormal functional test ( e.g . fractional flow reserve , stress test ) , unstable angina postinfarct angina . Lesion ( ) must locate native coronary artery RVD visual estimation ≥ 2.5 mm ≤4.0 mm . Lesion ( ) must locate native coronary artery length visual estimation ≤ 25 mm . 3 . Each target lesion may cover one stent . General 1 . Within 1 week acute myocardial infarction myocardial enzymes return normal ; 2 . Implantation stent target vessel within 1 year , patient plan intervention within six month ; 3 . Severe congestive heart failure ( NYHA III ) , leave ventricular ejection fraction &lt; 40 % ( ultrasound leave ventricular angiography ) ; 4 . Preoperative renal function serum creatinine &gt; 2.0mg/DL ; receive hemodialysis ; 5 . Bleeding , active gastrointestinal ulcer , brain hemorrhage subarachnoid hemorrhage half year history ischemic stroke , antiplatelet agent would allow anticoagulant therapy contraindication patient undergo antithrombotic therapy ; 6 . Aspirin , clopidogrel , heparin , contrast agent , poly lactic acid polymer rapamycin allergy ; 7 . The patient 's life expectancy le 12 month ; 8 . Top participate drug medical device meet primary study endpoint clinical trial time frame ; 9 . Researchers determine patient compliance poor , unable complete study accordance requirement ; 10 . Heart transplantation patient ; 11 . The unstable arrhythmia , high risk ventricular extrasystole ventricular tachycardia ; 12 . Cancer need chemotherapy ; 13 . Immunosuppression autoimmune disease , plan undergoing immunosuppressive therapy ; 14 . Planning receive longterm anticoagulant therapy , heparin , warfarin , etc ; 15 . Within six month elective surgery require stop aspirin , Clopidogrel patient ; 16 . Blood test prompt platelet count less 100x10E9/L great 700x10E9/L , white blood cell 3x10E9/L ; know suspect liver disease ( hepatitis ) ; 17 . Peripheral vascular disease , 6F catheter available . Angiographic 1. leave main coronary artery disease ; 2. severe triple vessel lesion require revascularization . The following exclusion criterion apply target lesion ( ) target vessel ( ) : 1 . Aortoostial right coronary artery ( RCA ) lesion ( within 3 mm ostium ) . 2 . Lesion locate within 3 mm origin Left Anterior Descending Artery ( LAD ) leave circumflex artery ( LCX ) . 3 . Lesion involve bifurcation : 1. side branch ≥ 2.5 mm diameter , 2. side branch diameter stenosis ≥ 50 % , 3. side branch require guide wire , 4. side branch require dilatation . 4 . Anatomy proximal within lesion may impair delivery Firesorb XIENCE stent : 1 . Extreme angulation ( ≥ 90° ) proximal within target lesion . 2 . Excessive tortuosity ( ≥ two 45° angle ) proximal within target lesion . 3 . Moderate heavy calcification proximal within target lesion . 5 . Lesion vessel involve myocardial bridge . 6 . Vessel contain thrombus indicate angiographic image IVUS OCT. 7 . Vessel previously treat stent time prior index procedure Firesorb XIENCE would need cross stent reach target lesion . 8 . Vessel previously treat target lesion within 5 mm proximal distal previously treat lesion . 9 . Lesion prevents successful balloon predilatation , define full balloon expansion follow outcome : 1 . Residual % DS maximum &lt; 40 % ( per visual estimation ) , ≤ 20 % strongly recommend . 2 . TIMI Grade3 flow ( per visual estimation ) . 3 . No angiographic complication ( e.g . distal embolization , side branch closure ) . 4 . No dissection National Heart Lung Blood Institute ( NHLBI ) grade DF . 5 . No chest pain last &gt; 5 minute . 6 . No ST depression elevation last &gt; 5 minute .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Bioresorbable Vascular Scaffold</keyword>
</DOC>